We validated the survival associations of GJB2 and SCN9A expression in two independent GBM cohorts, including 136 samples from the Glioma Longitudinal Analysis (GLASS) (Glass Consortium, 2018) and 55 samples from an earlier microarray dataset (Freije et al, 2004) (Fig. 3B). The gene discussed is SCN9A; the disease is central nervous system cancer.